Merus B.V.

Company Profile

Merus’ technologies are ideally suited to address multiple targets in a single therapeutic product. The key to the multispecific antibody therapeutics generated by Merus is a common light chain (cLC) shared by individual antibodies. With MeMo®, Oligoclonics® and Biclonics™, Merus has built a strong technology base to expand a pipeline of innovative cLC antibody products.

Merus discovers and develops innovative therapeutic human multispecific antibodies with improved clinical efficacy based on its common light chain (cLC) antibody technologies

Contact Merus B.V.

Padualaan 8 (postvak 133)
3584 CH Utrecht
+49 (0)40 88 16 59 64
Company Website

Request Info